Experience with more than 100 total artificial heart implants

Jack G. Copeland, Hannah Copeland, Monica Gustafson, Nicole Mineburg, Diane Covington, Richard G. Smith, Mark J Friedman

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Objective: The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods: Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results: From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1-441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in 24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions: These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care.

Original languageEnglish (US)
Pages (from-to)727-734
Number of pages8
JournalJournal of Thoracic and Cardiovascular Surgery
Volume143
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Artificial Heart
Prostheses and Implants
Survival
Transplantation
Nervous System Trauma
Hospice Care
Heart-Assist Devices
Multiple Organ Failure
Heart Transplantation
Survivors
Registries
Cause of Death
Stroke
Hemorrhage
Morbidity
Transplants
Safety
Equipment and Supplies
Lung
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Copeland, J. G., Copeland, H., Gustafson, M., Mineburg, N., Covington, D., Smith, R. G., & Friedman, M. J. (2012). Experience with more than 100 total artificial heart implants. Journal of Thoracic and Cardiovascular Surgery, 143(3), 727-734. https://doi.org/10.1016/j.jtcvs.2011.12.002

Experience with more than 100 total artificial heart implants. / Copeland, Jack G.; Copeland, Hannah; Gustafson, Monica; Mineburg, Nicole; Covington, Diane; Smith, Richard G.; Friedman, Mark J.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 143, No. 3, 03.2012, p. 727-734.

Research output: Contribution to journalArticle

Copeland, JG, Copeland, H, Gustafson, M, Mineburg, N, Covington, D, Smith, RG & Friedman, MJ 2012, 'Experience with more than 100 total artificial heart implants', Journal of Thoracic and Cardiovascular Surgery, vol. 143, no. 3, pp. 727-734. https://doi.org/10.1016/j.jtcvs.2011.12.002
Copeland JG, Copeland H, Gustafson M, Mineburg N, Covington D, Smith RG et al. Experience with more than 100 total artificial heart implants. Journal of Thoracic and Cardiovascular Surgery. 2012 Mar;143(3):727-734. https://doi.org/10.1016/j.jtcvs.2011.12.002
Copeland, Jack G. ; Copeland, Hannah ; Gustafson, Monica ; Mineburg, Nicole ; Covington, Diane ; Smith, Richard G. ; Friedman, Mark J. / Experience with more than 100 total artificial heart implants. In: Journal of Thoracic and Cardiovascular Surgery. 2012 ; Vol. 143, No. 3. pp. 727-734.
@article{a9476591c627404e8c86376e6642ed4b,
title = "Experience with more than 100 total artificial heart implants",
abstract = "Objective: The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods: Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results: From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9{\%} of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1-441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9{\%} of cases and take-back for hemorrhage in 24.7{\%} of cases. Survival to transplantation was 68.3{\%}. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8{\%}, 60.5{\%}, and 41.2{\%}, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions: These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care.",
author = "Copeland, {Jack G.} and Hannah Copeland and Monica Gustafson and Nicole Mineburg and Diane Covington and Smith, {Richard G.} and Friedman, {Mark J}",
year = "2012",
month = "3",
doi = "10.1016/j.jtcvs.2011.12.002",
language = "English (US)",
volume = "143",
pages = "727--734",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Experience with more than 100 total artificial heart implants

AU - Copeland, Jack G.

AU - Copeland, Hannah

AU - Gustafson, Monica

AU - Mineburg, Nicole

AU - Covington, Diane

AU - Smith, Richard G.

AU - Friedman, Mark J

PY - 2012/3

Y1 - 2012/3

N2 - Objective: The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods: Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results: From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1-441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in 24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions: These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care.

AB - Objective: The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods: Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results: From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1-441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in 24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions: These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care.

UR - http://www.scopus.com/inward/record.url?scp=84862777677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862777677&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2011.12.002

DO - 10.1016/j.jtcvs.2011.12.002

M3 - Article

C2 - 22245242

AN - SCOPUS:84862777677

VL - 143

SP - 727

EP - 734

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 3

ER -